These findings suggest the intriguing possibilities of manipulating SHP for the treatment of liver cancer and several metabolic diseases such as hypercholesterolemia, obesity, diabetes, and fatty liver disease. Here, NR0B2 is linked to obesity due to melanocortin 4 receptor deficiency.